Trial Profile
A Retrospective Cohort Study to Evaluate the Rate of Good Responses to Lamivudine (LAM) Treatment in naive Chronic Hepatitis B (CHB) Patients With Certain Pre-treatment Characteristics.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Lamivudine (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; ViiV Healthcare
- 13 May 2011 Actual end date changed from Jan 2011 to Apr 2011 as reported by ClinicalTrials.gov.
- 11 Mar 2011 Actual end date (Jan 2011) added as reported by ClinicalTrials.gov.
- 11 Mar 2011 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.